CMS Open Payments · Program Year 2024
MediView XR, Inc.
MediView XR, Inc. reported $34,388.46 across General Payments, Research, and Ownership to 98 physicians and teaching hospitals across 102 transactions.
- $34.4K Below-median payer
- All-tracks total
- 102 Below-median volume
- Transactions
- 98 Below-median reach
- Recipients
- −$20.0K
- General Payments vs PY2023
MediView XR, Inc. reported $34,388.46 across all CMS Open Payments tracks (General + Research + Ownership) to 98 physicians and teaching hospitals in Program Year 2024 - ranking #1443 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $31,088.46, averaging $350.90 per recipient.
How MediView XR, Inc.'s $34.4K all-tracks total breaks down
MediView XR, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
21/100
Total payments
F
10/100
Transaction volume
F
11/100
Physician reach
F
11/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer mediview-xr-inc MediView XR, Inc.
$34.4K · #1443/1,925 · 0.0% industry · PY2024
- TOT $34.4K
- RANK #1443
- SHARE 0.0%
- TXN 102
- RCP 98
- CAT 4
- GEN $31.1K
- ΔGEN −$20.0K
- TOP1 28.1%
- PY 2024
Volume peers
Nearest volume peer: Cycle Pharmaceuticals Inc ($34.4K)
MediView XR, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
MediView XR, Inc.'s CMS-reported General Payments decreased by $20.0K (−39.2%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: MEDIVIEW XR, INC.PY2023: MEDIVIEW XR, INC.PY2024: MediView XR, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $51,129.86
- PY2024
- $31,088.46
What the Data Shows for MediView XR, Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For MediView XR, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
The 4-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $14.8K, accounting for 47.4% of this company's General Payments and 13 transactions.
General Payment Breakdown by Type
MediView XR, Inc. made 4 types of general payments. "Consulting Fee" is the largest category at $14.8K, 47.4% of General Payments.
MediView XR, Inc. reports 4 general-payment categories - the top three are Consulting Fee (47.4%), Travel and Lodging (28.1%), and Food and Beverage (17.8%). The remaining 1 category make up 6.6% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How MediView XR, Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $14.8K | 13 | 47.4% |
| Travel and Lodging | $8.7K | 30 | 28.1% |
| Food and Beverage | $5.5K | 52 | 17.8% |
| Education | $2.1K | 3 | 6.6% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $27,959.86 (89.9%) of $31,088.46 in this company's General Payments records across 16 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for MediView XR, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Charles Martin
$8,735.95 across 42 reported transactions
- 2
Gaurav Gadodia
$8,099.56 across 6 reported transactions
- 3
Anand Patel
$6,750.00 across 9 reported transactions
- 4
Bradley B. Pua
$3,319.77 across 12 reported transactions
- 5
Anupama Chauhan
$1,054.58 across 8 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
MediView XR, Inc. ranks #1443 of 1,925 by total payments (bottom 25% by spend) but is notably more concentrated than that alone would suggest -- #735 of 1,838 by HHI (top 40% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- elliquence, LLC : $336.3K total payments, HHI 2127
- Tosoh Bioscience, Inc. : $290.85 total payments, HHI 2118
- Meridian Bioscience Inc. : $173.7K total payments, HHI 2110
- Alaska Medical Technologies, Llc : $3.2K total payments, HHI 2108
- Ortho-Clinical Diagnostics, Inc. : $1.1M total payments, HHI 2099
- Endeavor Orthopaedics LLC : $427.85 total payments, HHI 2098
- MediView XR, Inc. (this company) : $31.1K total payments, HHI 2083
- Inquis Medical, Inc. : $58.0K total payments, HHI 2081
- Nexus Spine, LLC : $35.1K total payments, HHI 2077
- Integer Holdings Corporation : $54.0K total payments, HHI 2076
- Central California Surgical Distributors, LLC : $321.5K total payments, HHI 2076
- Circa Scientific, Inc. : $16.3K total payments, HHI 2069
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as MediView XR, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about MediView XR, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with MediView XR, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Olympus Winter & Ibe GmbH
ZSFab, Inc.
Dentsply Sirona Pty Limited
Active Medical, LLC
Captiox LLC
Put this to use
MediView XR, Inc. ranks #1443 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just MediView XR, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.